{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-172192","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.594621+00:00","generated_at":"2026-05-17T21:29:31.251947+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Bioventus enters $400M credit facility to refinance existing debt","bullets":["$100M revolving credit facility and $300M term loan A facility, maturing July 31, 2030.","Initial interest rate: Term SOFR + 2.50% margin, subject to performance grid (1.75%-2.75%).","$30M drawn on revolver at closing; proceeds used to refinance existing 2019 credit facilities.","Financial covenants: max total net leverage ratio 4.00x (step down to 3.50x), min interest coverage 2.50x.","Facility secured by substantially all assets; includes $7.5M L/C and $7.5M swingline subfacilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-172192","json":"https://secwatch.observer/filing/0001193125-25-172192.json","markdown":"https://secwatch.observer/filing/0001193125-25-172192.md","text":"https://secwatch.observer/filing/0001193125-25-172192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000119312525172192/0001193125-25-172192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000119312525172192/d865758d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:29:31.251947+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bd489c02952fe6fdef18be10ac86bccb4f3047f","claim":"Bioventus Inc. incurred credit facility of a $100 million revolving credit facility and a $300 million first lien term loan A facility with Wells Fargo Bank, National Association at Term SOFR plus a margin of 2.50% maturing July 31, 2030.","evidence_excerpt":"On July 31, 2025 (the “Closing Date”), Bioventus LLC, a Delaware limited liability company and subsidiary of Bioventus Inc. (“Bioventus LLC” or the “Company”) and certain of its subsidiaries entered into a Credit Agreement (the “2025 Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent, and the lenders and other financial institutions party thereto. Pursuant to the 2025 Credit Agreement, the Company entered into a $100 million revolving credit facility (the “Revolving Credit Facility”) and a $300 million first lien term loan A facility (the “Term Loan Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000119312525172192/0001193125-25-172192-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"a $100 million revolving credit facility and a $300 million first lien term loan A facility"},{"label":"Counterparty","value":"Wells Fargo Bank, National Association"},{"label":"Rate","value":"Term SOFR plus a margin of 2.50%"},{"label":"Maturity","value":"July 31, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}